VANCOUVER, Aug. 13, 2018 /CNW/ - BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation, today announced the appointment of Joseph C. Sardano to its board of directors.
A recognized leader in the healthcare industry, Mr. Sardano is Chairman of the Board, President and CEO of Sensus Healthcare, Inc. (NASDAQ: SRTS), which specializes in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT). Mr. Sardano's appointment as BirchBioMed's first independent director is effective immediately.
"We are pleased to have Mr. Sardano join us in our innovative and cutting-edge efforts," said BirchBioMed Chairman and CEO Mark Miller. "His expertise in the healthcare industry, coupled with his company's advanced therapies, makes him an excellent addition to our Board. His management and marketing prowess bring a vital level of expertise to our team, as we seek to develop our ground-breaking treatments and get them into the hands of physicians and patients."
Mr. Sardano brings with him more than 30 years of healthcare management and marketing expertise. He has a strong track record of introducing and commercializing new technologies and services in many areas, including electronic brachytherapy, PET and PET/CT, SPECT, MRI, lithotripsy and digital radiography. Prior to his position at Sensus, he held leadership and management roles at CTI Molecular Imaging, GE Medical Systems, Siemens Medial Systems and Toshiba America Medical Systems, to name a few.
"BirchBioMed has the means to provide cost-effective products that will work in conjunction with Sensus' SRT to prevent and/or eliminate scarring," said Sardano. "This is all about creating better products at a lower cost for patients with scars, and especially keloids, and this collaboration will ultimately create more effective options for both doctors and patients moving forward."
BirchBioMed and Sensus teamed up in early 2018 to further research into using its ground-breaking fibrosis-targeted treatments, including FS2, in conjunction with Sensus' SRT.
BirchBioMed Inc. is a biomedical company focused on the commercialization, clinical evaluation and development of proprietary anti-scarring drugs, autoimmune therapeutics/therapies and novel strategies for transplantation. As a University of British Columbia (UBC) spinoff, BirchBioMed holds the exclusive, worldwide pharmaceutical license for two medical therapeutic technologies from UBC, which the university considers to be significant medical breakthroughs in the treatment of scarring and certain autoimmune diseases
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
For further information: Susan Elliott, Chief Marketing Officer, BirchBioMed Inc., Phone: (905) 833-0826, [email protected], birchbiomed.com